The profile contains critical company information including:
- Business description - A detailed description of the company’s operations and business divisions.
- Corporate strategy - Analyst’s summarization of the company’s business strategy.
- SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history - Progression of key events associated with the company.
- Major products and services - A list of major products, services and brands of the company.
- Key competitors - A list of key competitors to the company.
- Key employees - A list of the key executives of the company.
- Executive biographies - A brief summary of the executives’ employment history.
- Key operational heads - A list of personnel heading key departments/functions.
- Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights
ProMIS Neurosciences Inc. is a clinical-stage biotechnology company focused on discovering and developing therapeutic antibodies for neurodegenerative diseases caused by abnormal, misfolded proteins. The company targets conditions such as multiple system atrophy, amyotrophic lateral sclerosis, and Alzheimer’s disease, where toxic protein conformations drive disease progression. Its lead program, PMN310, is a monoclonal antibody being developed for Alzheimer’s disease. ProMIS uses a patented technology platform to design antibody candidates that selectively recognize and neutralize toxic forms of proteins while avoiding interference with the normal, healthy proteins required for cellular function. ProMIS is headquartered in Toronto, Ontario, Canada.ProMIS Neurosciences Inc Key Recent Developments
- Apr 13, 2026: ProMIS Neurosciences to Present at 2026 Bloom Burton & Co. Healthcare Investor Conference
- Mar 19, 2026: ProMIS Unveils Vaccines Targeting ALS and Parkinson's Disease
- Jan 30, 2026: ProMIS Neurosciences Announces Up to $175 Million Private Placement Financing
- Dec 10, 2025: ProMIS Neurosciences Publishes Peer-Reviewed Study on Selective Targeting of Toxic Oligomers and Reduced ARIA Risk
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Table of Contents
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Grifols SA
- Filana Therapeutics Inc
- Annovis Bio Inc
- Acumen Pharmaceuticals Inc
- Takeda Pharmaceutical Co Ltd
- Neurimmune Holding AG
- Inova Diagnostics Inc
- Idexx Laboratories Inc
- Diagnostica Stago Inc
- Chugai Pharmaceutical Co Ltd
- Novartis AG
- Eli Lilly and Co
- DiaSorin SpA
- Biogen Inc
- Anavex Life Sciences Corp
- Alzheon Inc
- LeonaBio Inc
- Eisai Co Ltd
- AbbVie Inc
- Kalgene Inc
- Biohaven Pharmaceuticals Inc
- Prothena Biosciences Inc
- WaveBreak Therapeutics Ltd
- Cognition Therapeutics Inc
- Alzinova AB
- AC Immune SA

